Abstract
Our retrospective study compared genotypic antimicrobial resistance in Mycoplasma genitalium–positive specimens collected from 48 community and 33 sexual health clinic (SHC) patients. Macrolide resistance was similar in community (75%) and SHC (76%) patients. We observed no significant difference in fluoroquinolone resistance between community (19%) and SHC (27%) patients (p = 0.66).
Highlights
Our retrospective study compared genotypic antimicrobial resistance in Mycoplasma genitalium–positive specimens collected from 48 community and 33 sexual health clinic (SHC) patients
Molecular approaches are the preferred method of M. genitalium detection, and resistance is determined genotypically. 23S rRNA mutations are associated with macrolide resistance and azithromycin treatment failures [1,2,3], whereas fluoroquinolone resistance is associated with mutations in the quinolone resistance–determining region, in the gyrA and parC genes [4]
A high proportion (72%) of macrolide resistance has been reported in sexual health clinic (SHC) patients in our region [5], and elsewhere in New Zealand fluoroquinolone resistance is reported in 23.3% of M. genitalium–positive specimens from SHC attendees [3], consistent with the high prevalence of macrolide and fluoroquinolone resistance in the Asia–Pacific region [1,3,6]
Summary
Our retrospective study compared genotypic antimicrobial resistance in Mycoplasma genitalium–positive specimens collected from 48 community and 33 sexual health clinic (SHC) patients. Macrolide resistance was similar in community (75%) and SHC (76%) patients. A high proportion (72%) of macrolide resistance has been reported in sexual health clinic (SHC) patients in our region [5], and elsewhere in New Zealand fluoroquinolone resistance is reported in 23.3% of M. genitalium–positive specimens from SHC attendees [3], consistent with the high prevalence of macrolide and fluoroquinolone resistance in the Asia–Pacific region [1,3,6]. The Study We performed a retrospective study of all specimens referred to the Microbiology Department at Auckland City Hospital (Auckland, New Zealand) for M. genitalium testing in 2017.
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
